A detailed history of Geneos Wealth Management Inc. transactions in Novavax Inc stock. As of the latest transaction made, Geneos Wealth Management Inc. holds 984 shares of NVAX stock, worth $7,931. This represents 0.0% of its overall portfolio holdings.

Number of Shares
984
Previous 984 -0.0%
Holding current value
$7,931
Previous $12,000 -0.0%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Oct 11, 2023

SELL
$6.81 - $9.74 $1,702 - $2,435
-250 Reduced 20.26%
984 $7,000
Q3 2022

Nov 14, 2022

SELL
$18.2 - $76.12 $15,215 - $63,636
-836 Reduced 40.39%
1,234 $22,000
Q2 2022

Jul 22, 2022

BUY
$36.28 - $75.29 $9,469 - $19,650
261 Added 14.43%
2,070 $106,000
Q1 2022

May 16, 2022

BUY
$69.73 - $142.9 $70,008 - $143,471
1,004 Added 124.72%
1,809 $133,000
Q4 2021

Feb 09, 2022

BUY
$134.56 - $217.97 $57,188 - $92,637
425 Added 111.84%
805 $115,000
Q2 2021

Jul 08, 2021

SELL
$121.0 - $257.67 $24,684 - $52,564
-204 Reduced 34.93%
380 $82,000
Q1 2021

Jun 17, 2021

BUY
$112.98 - $319.93 $28,696 - $81,262
254 Added 76.97%
584 $138,000
Q4 2020

May 19, 2021

BUY
$78.74 - $139.5 $18,110 - $32,085
230 Added 230.0%
330 $23,000
Q3 2020

Sep 07, 2021

SELL
$79.44 - $178.51 $45,678 - $102,643
-575 Reduced 85.19%
100 $11,000
Q2 2020

Sep 07, 2021

SELL
$13.86 - $83.61 $14,899 - $89,880
-1,075 Reduced 61.43%
675 $52,000
Q1 2020

Sep 07, 2021

BUY
$3.93 - $16.0 $6,877 - $28,000
1,750 New
1,750 $22,000
Q4 2019

Sep 07, 2021

SELL
$3.69 - $5.22 $756 - $1,070
-205 Closed
0 $0
Q2 2019

Sep 07, 2021

BUY
$4.93 - $12.2 $1,010 - $2,501
205 New
205 $1,000

Others Institutions Holding NVAX

About NOVAVAX INC


  • Ticker NVAX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 78,215,104
  • Market Cap $630M
  • Description
  • Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; Nan...
More about NVAX
Track This Portfolio

Track Geneos Wealth Management Inc. Portfolio

Follow Geneos Wealth Management Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Geneos Wealth Management Inc., based on Form 13F filings with the SEC.

News

Stay updated on Geneos Wealth Management Inc. with notifications on news.